Distinguished in Clear Cell Sarcoma

Dr. Julie A. Kish

Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
10920 Mckinley Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Distinguished in Clear Cell Sarcoma
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
10920 Mckinley Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Kish is an Oncologist in Tampa, Florida. Dr. Kish is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Laryngeal Cancer, and Clear Cell Sarcoma. Dr. Kish is currently accepting new patients.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
10920 Mckinley Dr, Tampa, FL 33612
Other Locations
H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Interleukin-2
Study Phase: Phase 2
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Cetuximab
Study Phase: Phase 1/Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, IRX-2
Study Phase: Phase 1
A Phase 1b Study of Adaptive Androgen Deprivation Therapy for State IV Castration Sensitive Prostate Cancer
A Phase 1b Study of Adaptive Androgen Deprivation Therapy for State IV Castration Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drugs: Abiraterone, Prednisone
Study Phase: Early Phase 1
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Abiraterone Acetate
Study Phase: Early Phase 1
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Enrollment Status: Completed
Publish Date: August 21, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 1
View 7 Less Clinical Trials

22 Total Publications

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Journal: The Lancet. Oncology
Published: April 09, 2024
Similar Doctors
Distinguished in Clear Cell Sarcoma
Dr. Jingsong L. Zhang
Oncology
Distinguished in Clear Cell Sarcoma
Dr. Jingsong L. Zhang
Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
888-860-2778
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Jingsong Zhang is an Oncologist in Tampa, Florida. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), and Liver Embolization. Dr. Zhang is currently accepting new patients.

Distinguished in Clear Cell Sarcoma
Dr. Jad Chahoud
Oncology | Hematology
Distinguished in Clear Cell Sarcoma
Dr. Jad Chahoud
Oncology | Hematology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jad Chahoud is an Oncologist and a Hematologist in Tampa, Florida. Dr. Chahoud is rated as an Elite provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Penile Cancer, Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Penectomy, and Nephrectomy. Dr. Chahoud is currently accepting new patients.

Distinguished in Clear Cell Sarcoma
Dr. Mayer Fishman
Hematology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Mayer Fishman
Hematology | Oncology

Tampa General Medical Group Inc

2 Tampa General Cir, Fl 3, 
Tampa, FL 
 (8.1 miles away)
813-844-7585
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mayer Fishman is a Hematologist and an Oncologist in Tampa, Florida. Dr. Fishman is rated as an Elite provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kish's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile